Swedbank AB Purchases 3,000 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Swedbank AB increased its stake in Medpace Holdings by 4.4%, now owning 71,000 shares valued at about $22.3 million after purchasing 3,000 additional shares.
• Insider transactions revealed significant stock sales, with General Counsel Stephen P. Ewald and CEO August J. Troendle selling 3,000 and 48,487 shares respectively, leading to a total of $74.1 million in shares sold in the last quarter.
• Analysts have varied opinions on Medpace, with UBS downgrading the stock to a "sell" rating while others set new price targets, ranging from $305 to $510, indicating mixed sentiment on future performance.

Swedbank AB increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 4.4% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 71,000 shares of the company's stock after acquiring an additional 3,000 shares during the period. Swedbank AB owned about 0.25% of Medpace worth $22,284,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of MEDP. GAMMA Investing LLC grew its holdings in shares of Medpace by 37.1% during the first quarter. GAMMA Investing LLC now owns 307 shares of the company's stock worth $94,000 after purchasing an additional 83 shares during the last quarter. Inspire Investing LLC acquired a new stake in Medpace during the 1st quarter worth approximately $2,059,000. Voya Investment Management LLC grew its holdings in Medpace by 7.6% during the 1st quarter. Voya Investment Management LLC now owns 21,976 shares of the company's stock worth $6,696,000 after acquiring an additional 1,560 shares during the last quarter. Zeno Equity Partners LLP increased its position in Medpace by 2.6% in the 1st quarter. Zeno Equity Partners LLP now owns 62,304 shares of the company's stock valued at $18,983,000 after acquiring an additional 1,564 shares during the period. Finally, United Services Automobile Association bought a new position in shares of Medpace during the first quarter valued at $500,000. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Performance

Shares of NASDAQ MEDP traded down $2.40 during midday trading on Tuesday, hitting $495.70. 52,161 shares of the stock traded hands, compared to its average volume of 437,484. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $506.55. The business has a 50 day moving average price of $450.44 and a two-hundred day moving average price of $356.61. The company has a market cap of $13.92 billion, a PE ratio of 36.85, a P/E/G ratio of 3.14 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business had revenue of $603.31 million during the quarter, compared to analyst estimates of $537.70 million. During the same quarter in the previous year, the business posted $2.75 EPS. Medpace's quarterly revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on MEDP shares. TD Cowen reaffirmed a "sell" rating and set a $366.00 target price (up from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. Barclays raised their price objective on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. William Blair restated a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Rothschild Redb lowered shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 3rd. Finally, UBS Group cut shares of Medpace from a "neutral" rating to a "sell" rating and increased their price objective for the stock from $300.00 to $305.00 in a research report on Tuesday, July 29th. Two analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Reduce" and an average price target of $422.27.

Insiders Place Their Bets

In other Medpace news, General Counsel Stephen P. Ewald sold 3,000 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the sale, the general counsel directly owned 10,343 shares of the company's stock, valued at approximately $4,654,350. The trade was a 22.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 48,487 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $451.69, for a total value of $21,901,093.03. Following the completion of the transaction, the chief executive officer owned 962,615 shares in the company, valued at $434,803,569.35. This represents a 4.80% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 161,266 shares of company stock worth $74,111,427 in the last 90 days. Company insiders own 20.30% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.